Overview

Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of treatment with cinacalcet and with cinacalcet plus alendronate in controlling bone loss induced by primary hyperparathyroidism.
Phase:
Phase 4
Details
Lead Sponsor:
Istituto Auxologico Italiano
Treatments:
Alendronate
Cinacalcet
Cinacalcet Hydrochloride